Bosnia and Herzegovina vs United Kingdom of Great Britain and Northern Ireland: Statin use vs. average non-HDL cholesterol levels

Bosnia and Herzegovina
3.3
in 2018
United Kingdom of Great Britain and Northern Ireland
3.3
in 2018
Bosnia and Herzegovina rank
95th
United Kingdom of Great Britain and Northern Ireland rank
95th

Statin use vs. average non-HDL cholesterol levels over time

  • Bosnia and Herzegovina
  • United Kingdom of Great Britain and Northern Ireland
012345198019992018

How they compare

Bosnia and Herzegovina currently reports 3.3 against 3.3 in United Kingdom of Great Britain and Northern Ireland, a difference of 0.

Across all 39 years both countries report, United Kingdom of Great Britain and Northern Ireland has been ahead every year.

Bosnia and Herzegovina ranks 95th and United Kingdom of Great Britain and Northern Ireland ranks 95th of 191 countries.

United Kingdom of Great Britain and Northern Ireland has averaged higher in every one of the 4 decades both report.

Head to head by decade

Decade Bosnia and Herzegovina United Kingdom of Great Britain and Northern Ireland Difference Ahead
1980s 3.68 4.48 0.8 United Kingdom of Great Britain and Northern Ireland
1990s 3.7 4.25 0.55 United Kingdom of Great Britain and Northern Ireland
2000s 3.55 3.89 0.34 United Kingdom of Great Britain and Northern Ireland
2010s 3.36 3.48 0.1222 United Kingdom of Great Britain and Northern Ireland

Averages of every year both report within each decade.

Frequently asked questions

Which has higher statin use vs. average non-hdl cholesterol levels, Bosnia and Herzegovina or United Kingdom of Great Britain and Northern Ireland?
Bosnia and Herzegovina, at 3.3 against 3.3 in United Kingdom of Great Britain and Northern Ireland as of 2018.
What is the difference in statin use vs. average non-hdl cholesterol levels between Bosnia and Herzegovina and United Kingdom of Great Britain and Northern Ireland?
0, with Bosnia and Herzegovina ahead.
How many years of comparable data are there for Bosnia and Herzegovina and United Kingdom of Great Britain and Northern Ireland?
39 years are reported by both, from 1980 to 2018.
How do Bosnia and Herzegovina and United Kingdom of Great Britain and Northern Ireland rank globally for statin use vs. average non-hdl cholesterol levels?
Bosnia and Herzegovina ranks 95th and United Kingdom of Great Britain and Northern Ireland ranks 95th of 191 countries.
Where does this data come from?
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

Share, cite or embed this page

Cite this page

Bosnia and Herzegovina vs United Kingdom of Great Britain and Northern Ireland: Statin use vs. average non-HDL cholesterol levels. Statizoid, drawing on World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data. Retrieved 08 September 2026, from https://reference.statizoid.com/compare/statin-use-vs-average-non-hdl-cholesterol-levels/bosnia-and-herzegovina/united-kingdom/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (Our World in Data); please keep the attribution.

<a href="https://reference.statizoid.com/compare/statin-use-vs-average-non-hdl-cholesterol-levels/bosnia-and-herzegovina/united-kingdom/">Bosnia and Herzegovina vs United Kingdom of Great Britain and Northern Ireland: Statin use vs. average non-HDL cholesterol levels</a> — Statizoid

About this data

Indicator
Statin use vs. average non-HDL cholesterol levels
Source
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
191 places, 7,449 data points, 1980–2018
Last refreshed

The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.